PROCEPT BioRobotics/$PRCT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
- Ticker
- $PRCT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 888
- Headquarters
- San Jose, United States
- Website
- www.procept-biorobotics.com
PRCT Metrics
BasicAdvanced
$1B
-
-$1.95
0.90
-
Price and volume
Market cap
$1B
Beta
0.9
52-week high
$38.11
52-week low
$16.67
Average daily volume
1.3M
Financial strength
Current ratio
6.547
Quick ratio
5.226
Long term debt to equity
0.221
Total debt to equity
0.228
Interest coverage (TTM)
-32.89%
Profitability
EBITDA (TTM)
-110.078
Gross margin (TTM)
64.22%
Net profit margin (TTM)
-32.54%
Operating margin (TTM)
-34.72%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-14.75%
Return on equity (TTM)
-30.24%
Valuation
Price to revenue (TTM)
2.925
Price to book
2.95
Price to tangible book (TTM)
2.95
Price to free cash flow (TTM)
-11.618
Free cash flow yield (TTM)
-8.61%
Free cash flow per share (TTM)
-1.507
Growth
Revenue change (TTM)
22.69%
Earnings per share change (TTM)
25.13%
3-year revenue growth (CAGR)
49.17%
3-year earnings per share growth (CAGR)
-5.80%
What the Analysts think about PRCT
Analyst ratings (Buy, Hold, Sell) for PROCEPT BioRobotics stock.
Analyst projections of the future price of PROCEPT BioRobotics stock.
Bulls say / Bears say
Q2 2026 revenue rose 19% to $94.5 million, and management maintained its full-year forecast of $390–410 million, implying 27–33% growth. That points to continued expansion despite softer-than-expected procedure activity. (GlobeNewswire)
HYDROS adoption is gaining traction: PROCEPT placed 65 systems in the US in Q2 at an average selling price of about $495,000, while HYDROS accounts recorded higher procedure activity per site than legacy AquaBeam accounts. Stronger utilisation could also lift recurring handpiece sales as the installed base grows. (GlobeNewswire)
The American Urological Association strengthened its recommendation for Aquablation, supporting its standing as a BPH treatment option. PROCEPT also completed enrolment in a 280-patient prostate-cancer trial and received FDA approval to begin a second randomised study, creating longer-term clinical and market opportunities if results support expansion. (BioPharmSignal, GlobeNewswire)
Q2 US procedure growth of 21% fell short of management’s expectations, largely because legacy AquaBeam sites were underperforming. PROCEPT lowered its 2026 US procedure outlook to 54,000–56,000, leaving execution and utilisation at older accounts as key risks. (The Motley Fool, GlobeNewswire)
Operating expenses rose to $89.8 million in Q2 from $73.9 million a year earlier, and the net loss widened to $26.9 million. Management expects a full-year adjusted EBITDA loss of $30–35 million, so growth still needs to translate into better operating leverage. (GlobeNewswire)
Q2 gross margin of 66% was partly helped by a $2.9 million tariff refund. That one-off boost makes the reported margin less dependable as a guide to underlying profitability and leaves the company exposed to cost and tariff pressures. (Last10K)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2026.
PRCT Financial Performance
Revenues and expenses
PRCT Earnings Performance
Company profitability
Upcoming events
No upcoming events
PRCT News
AllArticlesVideos
Kaplan Fox Encourages PROCEPT BioRobotics Corporation (PRCT) Investors to Take Immediate Action in the Securities Class Action Before September 22, 2026
Newsfile Corp2 weeks ago
Kaplan Fox Alerts PROCEPT BioRobotics Corporation (PRCT) Investors With Losses to a Securities Class Action - Act Before the September 22, 2026 Deadline
Newsfile Corp2 weeks ago
PRCT Deadline: Rosen Law Firm Urges PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Business Wire2 weeks ago
Funds containing PRCT
AllGBPEURUSD
Fund name | Fund size | $PRCT weighting |
|---|---|---|
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.